Literature DB >> 1652862

Demonstration of antibodies against bovine leukemia virus (BLV) by blocking ELISA using bovine polyclonal anti-BLV immunoglobulin.

P Have1, R Hoff-Jørgensen.   

Abstract

A blocking enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against bovine leukemia virus (BLV) is described. The test is based on the biotin-streptavidin system using unlabelled polyclonal bovine IgG against BLV as catching antibody and biotinylated bovine anti-BLV IgG as detecting antibody. The sensitivity was found to be 50-100 times higher than the agar gel immunodiffusion test, with a specificity of practically 100%. The blocking ELISA proved to be suitable for detection of antibodies against BLV in serum and milk. In 34 paired milk/serum samples, the average ratio of BLV antibody titres was 1:26. So far, more than 700,000 sera have been screened by blocking ELISA for BLV antibodies in the course of the Danish surveillance programme for BLV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652862     DOI: 10.1016/0378-1135(91)90149-a

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  3 in total

1.  Enzyme-linked immunosorbent assay for the diagnosis of bovine leukosis: comparison with the agar gel immunodiffusion test approved by the Canadian Food Inspection Agency.

Authors:  C Simard; S Richardson; P Dixon; C Bélanger; P Maxwell
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

2.  Antibody response against koala retrovirus (KoRV) in koalas harboring KoRV-A in the presence or absence of KoRV-B.

Authors:  O Olagoke; B L Quigley; M V Eiden; P Timms
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

3.  Induction of neutralizing antibody response against koala retrovirus (KoRV) and reduction in viral load in koalas following vaccination with recombinant KoRV envelope protein.

Authors:  O Olagoke; D Miller; F Hemmatzadeh; T Stephenson; J Fabijan; P Hutt; S Finch; N Speight; P Timms
Journal:  NPJ Vaccines       Date:  2018-08-02       Impact factor: 7.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.